Valuation: Cerus Corporation

Market Cap 601M 525M 482M 450M 853M 57.23B 867M 5.81B 2.25B 28.07B 2.26B 2.21B 96.72B P/E 2026 *
-90x
P/E 2027 * -901x
Enterprise Value 601M 525M 482M 450M 853M 57.23B 867M 5.81B 2.25B 28.07B 2.26B 2.21B 96.72B EV / Sales 2026 *
2.52x
EV / Sales 2027 * 2.31x
Free-Float
96.59%
Yield 2026 *
-
Yield 2027 * -
1 day+5.67%
1 week+19.70%
Current month+8.22%
1 month+11.27%
3 months+68.98%
6 months+53.40%
Current year+53.40%
1 week 2.78
Extreme 2.78
3.2
1 month 2.41
Extreme 2.41
3.2
Current year 1.62
Extreme 1.62
3.2
1 year 1.15
Extreme 1.15
3.2
3 years 1.12
Extreme 1.12
3.2
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 82 30/06/2015
Chief Executive Officer 51 30/06/2026
Director of Finance/CFO 54 03/05/2009
Director TitleAgeSince
Chairman 59 15/03/2026
Director/Board Member 72 23/03/2014
Director/Board Member 51 30/06/2026
Date Insider Type Main position Quantity % Market Cap.
06-08Sell

Director

-20,454 0.0102%
06-01Free

Director

60,000 0.0299%
06-01Free

Director

60,000 0.0299%
Change 5-day change 1-year change 3-year change Capi.($)
+5.33%+19.70%+113.51%+28.46% 601M
+4.20%+4.10%-17.69%+7.03% 120B
+2.92%-2.26%+0.67%-11.16% 12.33B
+7.83%+7.68%+44.69%+108.31% 8.08B
-0.64%+1.67%-48.31%-71.81% 4B
+1.85%+2.81%+18.98%+40.15% 2.57B
-1.23%+3.87%-12.07%-14.48% 1.86B
-0.41%+1.29%-5.26%-25.04% 1.62B
-3.31%-6.90%+221.83%+153.84% 1.58B
Average +1.99%+4.97%+35.15%+23.92% 16.98B
Weighted average by Cap. +4.02%+0.26%-9.91%+10.41%

Financials

2026 *2027 *
Net sales 238M 208M 191M 178M 338M 22.67B 343M 2.3B 892M 11.12B 894M 875M 38.31B 260M 227M 208M 194M 369M 24.74B 375M 2.51B 973M 12.13B 976M 954M 41.81B
Net income -6.24M -5.45M -5.01M -4.67M -8.85M -594M -9M -60.26M -23.35M -291M -23.42M -22.91M -1B -479K -419K -385K -359K -680K -45.63M -691K -4.63M -1.79M -22.38M -1.8M -1.76M -77.12M
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
02/07/26 US$3.160 +5.33% 3,286,638
01/07/26 US$3.000 +2.74% 4,909,418
30/06/26 US$2.920 -2.34% 2,174,286
29/06/26 US$2.990 +2.40% 2,341,268
26/06/26 US$2.920 +2.10% 7,434,823
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.000USD
Average target price
4.667USD
Spread / Average Target
+55.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock